Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGT-490 in PIK3CA-Mutated Solid Tumors
NCT07524322Phase 1Recruiting
- Sponsor
- Regor Therapeutics
- Start
- Jul 2026
- Primary completion
- Apr 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of RGT-490 in solid tumor, breast cancer, ovarian cancer and 2 more (2 arms), sponsored by Regor Therapeutics. Primary endpoints: Dose Limiting Toxicities at 4 weeks and Adverse Events and Serious Adverse Events at 12 months. Started Jul 2026; status: recruiting.
02
Drugs
RGT-490
03
Conditions
solid tumorbreast cancerovarian cancerendometrial cancer (EC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07524322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07524322.